Prosecution Insights
Last updated: April 19, 2026
Application No. 18/041,973

DOPA MODIFIED GELATIN FOR WOUND HEALING AND METHODS OF MAKING THE SAME

Non-Final OA §103
Filed
Feb 16, 2023
Examiner
TIEN, LUCY MINYU
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
BOSTON SCIENTIFIC CORPORATION
OA Round
1 (Non-Final)
62%
Grant Probability
Moderate
1-2
OA Rounds
3y 0m
To Grant
95%
With Interview

Examiner Intelligence

Grants 62% of resolved cases
62%
Career Allow Rate
45 granted / 72 resolved
+2.5% vs TC avg
Strong +33% interview lift
Without
With
+32.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
54 currently pending
Career history
126
Total Applications
across all art units

Statute-Specific Performance

§101
0.6%
-39.4% vs TC avg
§103
46.8%
+6.8% vs TC avg
§102
6.4%
-33.6% vs TC avg
§112
25.8%
-14.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 72 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Group I, claims 1-6, in the reply filed on 11/17/2025 is acknowledged. Accordingly, claims 7-20 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1-6 are rejected under 35 U.S.C. 103 as being unpatentable over Jus et al. (“Enzymatic cross-linking of gelatine with laccase and tyrosinase”, 2/1/2012, IDS reference) (hereinafter Jus). Jus discloses cross-linking of porcine gelatine by incubating for 24 hours with 150 U of tyrosinase, then heating the reaction mixture to deactivate the enzyme. (p. 89, § Chemical et seq.). Accordingly, Jus discloses providing a solution containing porcine gelatin, and incubating The prior art is not anticipatory insofar as this combination must be selected from various lists/locations in the reference. It would have been obvious, however, to make the combination since all the claimed elements were known in the prior art and one skilled in the art could have combined the elements as claimed by known methods with no change in their respective functions, and the combination yielded nothing more than predictable results to one of ordinary skill in the art. See MPEP § 2143 (I)(A). Regarding claim 2, Jus does not explicitly disclose an instantly claimed shear strength, burst pressure, load force, or tensile stress of the resulting cross-linked gelatin. However, since Jus discloses incubating substantially the same porcine gelatin and tyrosinase in substantially the same conditions, one of ordinary skill in the art would reasonably conclude the cross-linked gelatin of Jus to exhibit substantially the same characteristics, including a shear strength of at least 2 MPa; a burst pressure of at least 6 kPa; a load force of at least 60 N; and a tensile stress of at least 3 MPa like the claimed invention. Regarding claims 3 and 4 reciting an incubation time range (i.e. for more than 30 minutes) or a concentration of tyrosinase (i.e. between 100-200 U/ml), the claimed ranges would have been obvious to one of ordinary skill in the art since they overlap with the ranges of the prior art (i.e. 24 hours and 150 U, respectively). In the case where the claimed ranges "overlap or lie inside ranges disclosed by the prior art" a prima facie case of obviousness exists. See MPEP § 2144.05(I). Regarding claim 6, since Jus discloses providing substantially the same components (i.e. porcine gelatin and tyrosinase) and substantially the same process (i.e. incubating the solution containing porcine gelatin with tyrosinase) as instantly claimed, one of ordinary skill in the art would reasonably conclude the process of Jus makes the DOPA-gelatin in a one-step synthesis reaction like the claimed invention. Citation of Pertinent Prior Art The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Raia et al. (WO 2018/098299 A, 05/31/2018), directed to gelatin modified by one or more tyramine group, and the use of tyrosinase. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to LUCY TIEN whose telephone number is (571)272-8267. The examiner can normally be reached Monday - Thursday 8:30 AM - 6:30 PM EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, SAHANA KAUP can be reached at (571) 272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /LUCY M TIEN/Examiner, Art Unit 1612 /SAHANA S KAUP/Supervisory Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Feb 16, 2023
Application Filed
Jan 12, 2026
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12558321
Pharmaceutical Formulation
2y 5m to grant Granted Feb 24, 2026
Patent 12521352
TASTE MASKING DRUG FORMULATIONS
2y 5m to grant Granted Jan 13, 2026
Patent 12521335
COSMETIC COMPOSITIONS CONTAINING VITAMIN C COMPOUNDS AND USES THEREOF
2y 5m to grant Granted Jan 13, 2026
Patent 12516062
AGRICULTURAL OR HORTICULTURAL INSECTICIDE OR ANIMAL ECTOPARASITE OR ENDOPARASITE CONTROL AGENT EACH COMPRISING AN IMIDAZOPYRIDAZINE COMPOUND HAVING A SUBSTITUTED CYCLOPROPANE-OXADIAZOLE GROUP OR A SALT THEREOF AS ACTIVE INGREDIENT, AND METHOD FOR USING THE INSECTICIDE OR THE CONTROL AGENT
2y 5m to grant Granted Jan 06, 2026
Patent 12496340
VACCINE ADJUVANTS BASED ON TLR RECEPTOR LIGANDS
2y 5m to grant Granted Dec 16, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
62%
Grant Probability
95%
With Interview (+32.9%)
3y 0m
Median Time to Grant
Low
PTA Risk
Based on 72 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month